 2.6 Data Analysis. Data will be subjected to separate ANOVAANCOVA procedures SPSS, IBM Corp., Armonk NY. For each paradigm, endpoint measures will be analyzed by mixed ANOVAs, with between-group 2 levels: patients, controls and within-grouprepeated measures factors including drug caffeine, placebo. Analysis of EEGERP endpoints will also include scalp site as a within-group factor. Daily caffeine consumption as measured by the CCQ will be used as a covariate. Follow-up of significant Greenhouse-Geisser corrected main or interaction effects p .05 will be carried out with Bonferroni-adjusted planned comparisons using separate vs. pooled error estimates. In order to examine the correlation between behaviouralelectrophysiological endpoints and measures of caffeine consumption, two-tailed Spearmans rho correlations will be conducted between consumption measures and ERP amplitudeslatencies under placebo and drug conditions, as well as between consumption measures and measures of drug-associated change in ERP endpoints overall and within both groups. 